Research programme: G protein-coupled receptor modulators - Pfizer/Astellas Pharma
Alternative Names: GPCR modulators - Pfizer/AstellasLatest Information Update: 16 Mar 2022
At a glance
- Originator Arena Pharmaceuticals; Astellas Pharma
- Class
- Mechanism of Action G protein-coupled receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Neurological disorders
Most Recent Events
- 11 Mar 2022 Arena Pharmaceuticals has been acquired and merged into Pfizer
- 18 May 2007 Discontinued - Preclinical for Neurological disorders in Japan (unspecified route)
- 18 May 2007 Discontinued - Preclinical for Neurological disorders in USA (unspecified route)